Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 23 Urinary Bladder Neoplasms 22 Ureteral Neoplasms 8 Urologic Neoplasms 4 Urethral Neoplasms 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Neoplasms 3 Neoplasm Metastasis 3 Muscle Invasive Bladder Urothelial Carcinoma 2 Metastatic Urothelial Cancer 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Advanced Bladder Cancer 2 Urothelial Cancer 1 Urologic Diseases 1 Urogenital Neoplasms 1 Urogenital Diseases 1 Urinary Bladder Diseases 1 Urachal adenocarcinoma 1 Triple Negative Breast Neoplasms 1 Salivary Gland Neoplasms 1 Renal Pelvis and Ureter Urothelial Carcinoma 1 Peripheral Nervous System Diseases 1 Penile Squamous Cell Carcinoma (PSCC) 1 Penile Neoplasms 1 Pancreatic Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms by Site 1 Muscle-invasive Bladder Cancer 1 Metastatic Urothelial Cancer and Other Malignant Solid Tumors 1

Interventions

Nivolumab 143 pembrolizumab 129 Sunitinib 127 Bevacizumab 71 Everolimus 70 Sorafenib 68 cabozantinib 64 Ipilimumab 61 pazopanib 58 Axitinib 57 aldesleukin 51 Magnetic Resonance Spectroscopy 43 Cyclophosphamide 40 Interleukin-2 38 lenvatinib 36 Radiosurgery 36 Specimen Handling 33 Interferon-alpha 32 atezolizumab 29 belzutifan 24 temsirolimus 23 Gemcitabine 23 fludarabine phosphate 22 Radiotherapy 18 Interferon alpha-2 18 Biopsy 18 fludarabine 17 durvalumab 17 avelumab 17 Paclitaxel 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Carcinoma, Renal Cell × enfortumab vedotin × Clear all

NCT06302569 2025-09-09

REPRINT

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Recruiting

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡